MDT-AP-0602
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 11.040000000000001
- os_event
- true
- age_years
- 11
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.223170261
- umap2_2d
- 4.753894291
- umap1_3d
- 3.13376909
- umap2_3d
- -1.09302036
- umap3_3d
- -2.347689939
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.290
- DNA_REPAIR+0.170
- MYC_TARGETS_V1+0.150
- HEDGEHOG_SIGNALING+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.120
- HEME_METABOLISM+0.050
- PROTEIN_SECRETION+0.050
- HYPOXIA+0.040
- MYOGENESIS+0.030
- NOTCH_SIGNALING+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.490
- IL6_JAK_STAT3_SIGNALING-0.490
- INFLAMMATORY_RESPONSE-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- ANGIOGENESIS-0.330
- KRAS_SIGNALING_UP-0.310
- COMPLEMENT-0.290
- COAGULATION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1327975 | GTEX | — | 0.890 |
| 2 | SRR1477773 | GTEX | — | 0.885 |
| 3 | SRR5088889 | — | — | 0.884 |
| 4 | SRR1315842 | GTEX | — | 0.883 |
| 5 | ERR2208948 | — | — | 0.872 |
| 6 | ERR2598236 | fetal | fetal | 0.871 |
| 7 | SRR1331944 | GTEX | — | 0.870 |
| 8 | SRR1499442 | GTEX | — | 0.869 |
| 9 | SRR1403915 | GTEX | — | 0.869 |
| 10 | SRR663681 | GTEX | — | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |